Developed by the Spanish laboratory Hipra, the vaccine is designed as a booster dose against Covid-19.
Article written by
Posted
Update
Reading time : 1 min.
A new vaccine soon to be introduced on the European market? The European Commission announced on Tuesday August 2 the signing of a contract to acquire up to 250 million doses of the anti-Covid-19 vaccine developed by the Spanish pharmaceutical firm Hipra. The drug is still awaiting approval by the European regulator.
The aim is to complete the range of vaccines available to EU countries for “ensure a maximum level of preparedness as the autumn and winter months approach”, explained the Commissioner for Health, Stella Kyriakides, quoted in a press release. The head of the Spanish government Pedro Sanchez welcomed this announcement during a trip to the Balearic Islands.
The vaccine developed by Hipra, described as “a bivalent recombinant protein vaccine”, is being evaluated by the Netherlands-based European Medicines Agency. It is designed as a booster dose for people aged 16 or over, the Commission says. This vaccine is stored in a refrigerated state, between 2 and 8°C, which facilitates its storage and distribution in Europe and throughout the world, underlines the press release. If the vaccine receives a marketing authorisation, the fourteen EU countries participating in the joint procurement will be able to purchase it through the framework contract already in place.